Serum S100B Levels and Major Depressive Disorder: Its Characteristics and Role in Antidepressant Response

Byong-Su Jang, MD1
Hyeran Kim, MD, PhD1
Shinn-Won Lim, MS2
Ki-Won Jang, MA2
Doh-Kwan Kim, MD, PhD1,2
1Department of Psychiatry, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 2Center for Clinical Research, Samsung Biomedical Research Institute, Seoul, Korea

Objective S100B is a neurotrophic factor that is involved in neuroplasticity. Neuroplasticity is disrupted in depression; however, treatment with antidepressants can restore neuroplasticity. S100B has previously been used as a biological marker for neuropathology and neuroplasticity; therefore, in this study, we compared serum S100B levels in depressive patients to those of normal controls. In addition, we compared the serum S100B levels of antidepressant responders to those of nonresponders.

Methods Thirty five normal controls and 59 depressive patients were enrolled in this study. Depressive patients entered a 6 week clinical trial that included treatment with antidepressants. The serum S100B levels and clinical assessments, which included Hamilton depression rating scores, were measured at baseline and after 6 weeks of treatment with antidepressants. The difference in the serum S100B levels between depressive patients and normal controls and between antidepressant responders and nonresponders was then compared.

Results There were no significant differences in the serum S100B levels of normal controls and depressive patients. In addition, 30 of the depressive patients responded to antidepressant treatment while 29 did not. Finally, the responders had significantly higher baseline serum S100B levels than the nonresponders.

Conclusion The results of this study suggest that the baseline serum S100B level is associated with the subsequent response to antidepressants. In addition, the high baseline serum S100B level that was observed in depressive patients may enhance neuroplasticity, which results in a favorable therapeutic response to antidepressants.

KEY WORDS: S100B, Major depressive disorder, Antidepressant, Response, Neuroplasticity.

Introduction

Several recent studies have reported that a change in neuroplasticity is associated with the pathophysiology of depression. In depressive patients, the serum levels of growth factors are decreased, and neuroplasticity, a fundamental mechanism of neuronal adaptation, is disrupted. In addition, recovery from depression is also associated with neuroplasticity, and the time lag that occurs between the administration of antidepressants and the onset of therapeutic activity suggests that the therapeutic effect of antidepressants arises from enhanced neurogenesis and the induction of neuroplasticity.

S100B, which is one of the proteins involved in neuroplasticity, is located in glial cells in the human brain. SB100B is produced and secreted by astrocytes, and exerts paracrine and autocrine effects on neurons and glia. In addition, S100B is an acidic Ca\(^+\) binding protein that may influence several cellular responses along the Ca\(^+\)-signal transduction pathway. Additionally, S100B regulates cell shape, contraction, cell-to-cell communication, energy metabolism, intracellular signal transduction, and cell growth. Cell culture and animal experiments have shown that the effects of extracellular S100B depend on its concentration. For example, when it is present...
in nanomolar concentrations, S100B acts as a growth and differentiation factor for neurons and astrocytes. However, when it is present in micromolar concentrations, S100B exerts neurotoxic activity and induces the apoptosis of neurons and astrocytes.

Several studies have reported that depressive patients have increased levels of S100B in the serum and cerebrospinal fluid (CSF).\textsuperscript{17-20} For example, Rothermundt et al. reported that the serum S100B levels in depressive patients were higher than those in normal controls, and suggested that a high level of serum S100B might correspond to neuron growth and synaptogenesis during synaptic remodeling in depressive patients.\textsuperscript{17} Additionally, Arolt et al. reported that antidepressant responders had higher baseline serum S100B levels than nonresponders, and suggested that high serum S100B levels were related to a favorable therapeutic response.\textsuperscript{19} The results of these previous studies suggest that S100B participates in neuroplasticity, which is important in recovery from depression. Furthermore, these findings indicate that the serum S100B level can be used to predict an antidepressant treatment response.

In this study, we compared the serum S100B levels of depressive patients to those of normal controls. We also assessed the serum S100B levels of depressive patients before and after treatment with antidepressants and then compared the serum S100B levels of antidepressant responders to those of nonresponders.

**Methods**

**Subjects**

Fifty-nine depressive patients that participated in the Clinical Trials Program of the Samsung Medical Center Affective Disorder Clinic were enrolled in this study. Patients received a semistructured diagnostic interview using the Korean version of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV),\textsuperscript{22} and all patients fulfilled the DSM-IV criteria for major depressive disorder. Diagnoses were confirmed by a board certified psychiatrist. Exclusion criteria for this study included significant medical conditions, schizophrenia or other psychotic disorders, bipolar disorder, a history of alcohol or drug dependence, epilepsy, and organic mental disorders. All patients enrolled in this study were at least 18 years of age.

Normal controls were recruited by advertisement in local newspapers. Normal controls met the following criteria: a Beck depression inventory (BDI)\textsuperscript{23} score of less than 16; a score on the Korean version of the mini mental status exam (K-MMSE)\textsuperscript{24} within the normal limits for their age and education level; a 7 Minute Screening battery score\textsuperscript{25} within normal limits for their age and education level: a Seoul-Activities of Daily Living (S-ADL)\textsuperscript{26} score of 0, and a Seoul-Inventory Activities of Daily Living (S-IADL)\textsuperscript{26} score that was less than 8: no abnormal neurological signs. Normal controls were excluded based on the Healthy Screening Exclusion Criteria.\textsuperscript{27} Thirty five normal healthy controls were enrolled in this study.

The study protocol was approved by the institutional review board of Samsung Medical Center, Seoul, Korea. Signed informed consent was obtained from all participants.

**Procedure**

We obtained blood samples by venipuncture and then measured the serum S100B levels. In depressive patients, blood samples were obtained prior to treatment with antidepressants (baseline S100B) and after 6 weeks of treatment with antidepressants (S100B after treatment).

The severity of the depressive symptoms was rated using the 17-item Hamilton Rating Scale for Depression (HAM-D),\textsuperscript{23} which was administered by a single trained rater. The 17-item HAM-D scores were obtained at baseline and after 6 weeks of antidepressant treatment. A response was defined as a decrease in the HAM-D score of 50% or more at 6 weeks.

The rater and laboratory workers were blind to the purpose of the study. In addition, the rater was blind to the S-100B data, and the HAM-D scores were not disclosed to the laboratory workers. To maintain blindness, a trained research coordinator managed all data and schedules.

The clinician’s drug choice was based on the anticipated side effects and the symptomatic characteristics of the patients. The dosing protocol was flexible and conducted according to the clinician’s assessment of symptoms and side effects. Side effects were measured using the UKU Side Effect Rating Scale\textsuperscript{28} at each visit. Anxiolytics and sedative-hypnotics were permitted.

**Biochemical assay**

Venous blood was drawn using a serum-separating tube (SST) vacutainer, after which it was allowed to stand at room temperature for 30 min. The samples were then centrifuged at 3,000 rpm for 15 min. The supernatant was collected and frozen at −80°C until assay. Quantitation of the S100B serum levels was conducted using a CanAg S100 Enzyme immunoassay kit (CanAg Diagnostics AB, Sweden) according to the manufacturer’s instructions. This solid-phase, two-step, non-competitive immunoassay kit is based on two mouse monoclonal antibodies specific for two different epitopes expressed in S100B (S100A1B+S100BB). Briefly, calibrators and samples were incubated together with biotinylated Anti-S100B monoclonal antibody in Streptavidin
coated microtiter strips. S100B present in the calibrators or samples was then adsorbed to the Streptavidin coated microtiter wells by the biotinylated anti-S100B monoclonal antibody during incubation. The strips were then washed and incubated with horseradish peroxidase (HRP) labeled Anti-S100B monoclonal antibody. Next, buffered Substrate/Chromogen reagent (hydrogen peroxide and 3, 3’, 5, 5’ tetra-methylbenzidine) was added to each well, which resulted in the enzyme reaction developing a blue color if antigen was present. After adding stop solution, the absorbance values were gotten at 405 nm. All analyses were conducted in duplicate in a double-blind test using an electronic pipetter. The lower detection limit of the assay for S100 was 25 ng/L. The total imprecision for S100 was 25 ng/L. The imprecision of the intraassay conducted in duplicate in a double-blind test using an electronic pipetter. The lower detection limit of the assay was 10.5% at 0.054 ug/L, 7.6% at 0.490 ug/L, and 0.8% at 1.5 ug/L. The total imprecision (between-day, CVs) was 10.5% at 0.054 ug/L, 7.6% at 0.490 ug/L, and 0.8% at 1.5 ug/L.

**Data analysis**

The means and standard deviations (SDs), ranges of continuous variables, and proportions of categorical variables were determined. Specifically, a T-test was used to evaluate continuous variables and a χ² test was used for categorical variables. Accordingly, we compared the serum S100B levels of the depressive patients and normal controls using a T-test. Similarly, we compared the serum S100B levels of antidepressant responders and nonresponders at baseline and after treatment using a T-test. We then used multiple logistic regression analysis to determine if the S100B levels were different between antidepressant responders and nonresponders after adjusting for sex, age, body mass index (BMI, weight/height²), family history, episode numbers, onset age, and the duration of the current episode. In this analysis, treatment response was considered to be a dependent variable. All differences were considered to be significant at p<0.05.

**Subject characteristics**

Of the 35 normal controls, 24 (69%) were female, and of the 59 depressive patients, 43 (73%) were female. The mean age of the normal controls was 61.8, and the mean age of the depressive patients was 60.3. The mean BMI of the normal healthy controls was 24.9 kg/m² and the mean age of the depressive patients was 24.1 kg/m². There were no significant differences in the mean sex ratio, age, or BMI of the depressive patients and the normal controls (Table 1).

A total of 59 depressive patients received antidepressants. Twenty two patients received mirtazapine, 29 patients received selective serotonin reuptake inhibitors (SSRIs) (fluoxetine, n=21; paroxetine, n=4; sertraline, n=3; and escitalopram, n=1), 3 patients received venlafaxine, 2 patients received nortriptyline, 1 patient received bupropion, and 2 patients received agomelatine. Of the 59 depressive patients, 30 were responders and 29 patients were nonresponders. Of the 30 responders, 14 received mirtazapine, 12 received SSRIs (fluoxetine, n=9; paroxetine, n=2; and sertraline, n=1), 1 received nortriptyline, 1 received bupropion, and 2 received agomelatine. Of the 29 nonresponders, 8 received mirtazapine, 17 received SSRIs (fluoxetine, n=12; paroxetine, n=2; sertraline, n=2; and escitalopram, n=1), 3 received venlafaxine, and 1 received nortriptiline. There were no differences in the mean sex ratio, age, BMI, family history, number of episodes, onset age, or duration of current episode between the responders and nonresponders (Table 1).

**Serum S100B levels**

The mean serum S100B level of the depressive patients was lower than that of the normal controls, but this difference was not statistically significant (64.1 ± 20.4 ng/L and 69.6 ± 16.4 ng/L, mean ± SD for depressive patients

**TABLE 1.** Demographic and clinical characteristics of study subjects

| Characteristics          | Normal controls (N=35) | Depressive patients (N=59) | p      |
|--------------------------|------------------------|---------------------------|--------|
|                          | All patients           | AD responder (N=30)       | AD nonresponder (N=29) |
| Sex, m/f*                | 11/24                  | 9/21                      | 7/22   | 0.655 |
|                         |                        |                           |        | 0.612 |
| Age, mean (SD)†          | 61.8 (8.5)             | 60.3 (12.6)               | 0.882  |
|                         |                        |                           |        | 0.940 |
| BMI, mean (SD)†          | 24.9 (2.8)             | 24.1 (2.6)                | 0.111  |
|                         |                        |                           |        | 0.867 |
| Onset age, mean (SD)†    | 55.4 (12.4)            | 51.1 (15.6)               | 0.244  |
|                         |                        |                           |        | 0.905 |
| Episode numbers, mean (SD)† | 2.8 (3.3)            | 2.1 (1.1)                 | 0.382  |
| Family history, Yes/No*  | 8/22                   | 5/24                      |        |
| Duration, months, mean (SD)† | 5.41 (5.5)        | 9.87 (10.5)               | 0.154  |

* χ² test, †T-test, ‡Mann-Whitney test. AD: antidepressant
and normal controls, respectively, \( p=0.111 \). When the serum S100B levels of antidepressant responders and nonresponders were compared at baseline, the S100B level of the responders was significantly higher than that of the nonresponders (68.6 ng/L for responders and 57.4 ng/L for nonresponders, \( p=0.048 \), Figure 1). After adjusting for sex, age, BMI, family history, number of episodes, onset age, and duration of the current episode, the baseline serum S100B levels of the responders were significantly higher than those of the nonresponders \((\chi^2=5.31, df=1, OR=1.10, 95\% CI: 1.01-1.10, p=0.02)\).

After 6 weeks of antidepressant treatment, the serum S100B levels of the antidepressant responders and nonresponders did not differ significantly \((69.8 \pm 19.5 \text{ ng} / \text{L} \text{ vs } 64.0 \pm 21.3 \text{ ng} / \text{L})\). However, the serum S100B level increased after treatment with antidepressants, and this increase was more prominent in responders than in nonresponders. Specifically, the mean serum S100B level of the non-responders increased by 6.6 ng/L (57.4 ng/L to 64.0 ng/L), but the mean serum S100B level of the responders only increased by 1.2 ng/L (68.6 ng/L to 69.8 ng/L).

**Discussion**

The results of this study indicate that the serum S100B levels did not differ between depressive patients and normal controls. However, depressive patients with high baseline serum S100B levels responded better to treatment with antidepressants than those with low baseline serum S100B levels. In addition, the serum S100B level increased in response to treatment with antidepressants.

In the present study, antidepressant responders had higher baseline serum S100B levels than non-responders. There are two causes of increased serum S100B levels, brain damage, and functional secretion by astrocytes. Mathematical models suggest that serum S100B levels above 350 ng/L indicate brain damage. In our study, the serum S100B levels were lower than 350 ng/L, which indicates that the levels observed in this study reflect functional secretion by astrocytes. S100B is known to have neurotrophic effects when it is present in response to functional secretion. For example, S100B enhances the growth and differentiation of neurons and astrocytes.

In addition, S100B induces neurogenesis, which is essential to the behavioral effects of antidepressants. The results of this study suggest that the baseline serum S100B level is associated with enhancement of the growth and differentiation of neurons, which results in a favorable therapeutic response to antidepressants.

The results of previous studies comparing the serum S100B levels of depressive patients and normal controls showed that depressive patients had higher serum S100B levels than normal controls. However, there was no difference in the serum S100B levels of depressive patients and normal controls observed in the present study. It is important to note that there were several differences between the patient populations of the present study and those of previously conducted studies. Specifically, the depressive patients enrolled in previous studies were inpatients that had mean HAM-D scores that were greater than 25. Conversely, in the present study, the patients were outpatients with a mean HAM-D score of 19. However, the results of a previous study revealed a positive correlation between the severity of depression and serum S100B levels in depressive patients. This finding is similar to the results of the present study, in which there was a positive correlation between the HAM-D scores and the serum S100B levels \((r=0.364, p=0.005)\). Therefore, the difference in the results of the present study and previously conducted studies may stem from differences in the severity of depression in the patient populations.

Another explanation for these differences may be the heterogeneity of neurotrophic activity in depressive patients. Neuroplasticity is disrupted in depression. In response, the brain attempts to restore neuroplasticity by increasing the S100B levels in depressive patients. However, the compensatory mechanism varies among depressive patients. As a result, some depressive patients have high concentrations of S100B, while others have low concentrations. Overall, the results of the present study indicate that the S100B levels of the depressive patients did not differ significantly from those of the normal controls. Moreover, neurotrophic activity is an indicator of a...
compensatory response to disrupted neuroplasticity, which is related to antidepressant response. Antidepressants exert their effects by increasing neurogenesis and modulating the signaling pathways involved in neuroplasticity. Therefore, the levels of neuroplasticity in depressive patients can affect their response to antidepressants.

We also found that the serum S100B level increased after antidepressant treatment. Antidepressants stimulate the secretion of neurotrophic factors, such as brain-derived neurotrophic factor (BDNF). Antidepressants also enhance the secretion of S100B by astrocytes via serotonergic systems. Interestingly, in this study, the increase in serum S100B levels in response to treatment with antidepressants was more prominent in nonresponders than in responders. Furthermore, in the present study patients with high baseline serum S100B levels were clinically improved within 6 weeks of treatment with antidepressants, but the increases in their serum S100B levels during 6 weeks of antidepressant treatment were minimal. Additionally, patients with low baseline serum S100B levels were not improved clinically within 6 weeks of treatment with antidepressants, but their serum S100B levels were much higher after 6 weeks of antidepressant treatment. In contrast to our findings regarding the levels of S100B, BDNF is known to increase more in responders than in nonresponders following antidepressant treatment. These findings suggest that S100B and BDNF play different roles in the recovery of depression. One explanation is that S100B may be a prerequisite for neuronal changes that is required to improve depression, whereas BDNF may reflect the current state of recovery.

There are several limitations to this study. First, various antidepressants were used in our study. However, all antidepressants exert an effect on neuroplasticity. Second, the mean age of the patients included in this study was in the 60s, which is higher than that of other studies. Third, our study was a short-term clinical trial that was only conducted for 6 weeks. Despite these limitations, this study is the largest serum S100B study performed in depressive patients to date and provides useful information regarding the relationship between serum S100B levels and depression. However, the results of this study need to be confirmed in a long-term depression study. In addition, further studies including younger depressive patients using only one type of antidepressant are also needed.

Acknowledgment

This study was supported by the Korea Science and Engineering Foundation (KOSEF) NRL program grant funded by Korean government (MEST) (ROA-2007-000-20129-0) and a grant from the Korea Health 21 R & D Project, Ministry of Health & Welfare, Republic of Korea (03-PJ10-PG13-GD01-0002).

REFERENCES

1. Karelde F, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry J-M. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 2002;109:143-148.
2. Duman RS. Synaptic plasticity and mood disorders. Mol Psychiatry 2002;7 Suppl 1: S29-34.
3. Pittenger C, Duman RS. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 2008;33:88-109.
4. Daszuta A, Ban M Sr, Sournier A, Hery M, Mocaer E. Depression and neuroplasticity: implication of serotonergic systems. Therapeutic 2005; 60:461-468.
5. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003;301:805-809.
6. Arantes-Goncalves F, Coelho R. Depression and treatment. Apoptosis, neuroplasticity and antidepressants. Acta Med Port 2006;19:9-20.
7. Henkel AW, Sperling W, Rotter A, Realbush U, Reichardt C, Bonsch D, et al. Antidepressant drugs modulate growth factors in cultured cells. BMC Pharmacol 2008:8-6.
8. Maya Vetencourt FJ, Sale A, Viegi A, Barconcini L, De Pasquale R, O'Leary OF, et al. The antidepressant fluoxetine restores plasticity in the adult visual cortex. Science 2008;320:385-388.
9. Manji HK, Moore GJ, Rajkowska G, Chen G. Neuroplasticity and cellular resilience in mood disorders. Mol Psychiatry 2000:5:578-593.
10. Schäfer BW, Heimann CW. The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends Biochem Sci 1996; 21:134-140.
11. Ponath G, Schettler C, Kaestner F, Voigt B, Wentker D, Arolt V, et al. Autocrine S100B effects on astrocytes are mediated via RAGE. J Neuroimmunol 2007;184:214-222.
12. Steiner J, Bernstein HG, Bielau H, Bernted A, Brisch R, Mawrin C, et al. Evidence for a wide extra-astrocytic distribution of S100B in human brain. BMC Neurosci 2007;8:2.
13. Donato R, S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 2001;33:637-668.
14. Santamaria-Kisiel L, Rintala-Dempsey AC, Shaw GS. Calcium-dependent and -independent interactions of the S100 protein family. Biochem J 2006;396:201-214.
15. Zimmer DB, Cornwall EH, Landar A, Song W. The S100 protein family: history, function, and expression. Brain Res Bull 1995;37:417-429.
16. Schmitt KR, Kern C, Lange PE, Berger F, Abdul-Khalig H, Hendrix S. S100B modulates IL-6 release and cytotoxicity from hypothermic brain cells and inhibits hypothermia-induced axonal outgrowth. Neurosci Res 2007;59:68-73.
17. Rothermundt M, Arolt V, Wiesmann M, Misssler U, Peters M, Rudolf S, et al. S100B is increased in melancholic but not in non-melancholic major depression. J Affect Disord 2001;66:89-93.
18. Schroeter ML, Abdul-Khalig H, Diefenbacher A, Blasig IE. S100B is increased in mood disorders and may be reduced by antidepressive treatment. Neuropeport 2002;13:1675-1678.
19. Arolt V, Peters M, Erfarhth A, Wiesmann M, Misssler U, Rudolf S, et al. S100B and response to treatment in major depression: a pilot study. Eur Neuropsychopharmacol 2003;13:235-239.
20. Schroeter ML, Abdul-Khalig H, Krebs M, Diefenbacher A, Blasig IE. Serum markers support disease-specific glial pathology in major depression. J Affect Disord. In press. 2008.
21. Kim DK, Lim SW, Lee S, Sohn SE, Kim S, Hahn CG, et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 2000;11:215-219.
22. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: American Psychiatric Association 1994.
23. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory

www.psychiatryinvestigation.org 197
for measuring depression. Arch Gen Psychiatry 1961;4:561-571.

24. Kang Y, Na DL, Hahn S. A validity study on the Korean Mini-Mental State Examination (K-MMSE) in dementia patients. J Korean Neurol Assoc 1997;15:300-308.

25. Ijuin M, Homma A, Minura M, Kitamura S, Kawai Y, Imai Y, et al. Validation of the 7-Minute Screen for the detection of early-stage Alzheimer’s disease. Dement Geriatr Cogn Disord 2008;25:248-255.

26. Ku HM, Lee HS. A study on the reliability and validity of Seoul-Activities of Daily Living (S-ADL). J Korean Geriatr Soc 2004;8:206-214.

27. Christensen KJ, Multhaup KS, Nordstrom S. A cognitive battery for dementia: development and measurement characteristics. J Consult Clin Psychol 1991;3:168-174.

28. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987;334:1-100.

29. Abdul-Khaliq H, Schubert S, Stoltenburg-Didinger G, Troitzsch D, Böttcher W, Höbler M, et al. Protein S-100beta in brain and serum after deep hypothermic circulatory arrest in rabbits: relationship to perivascular astrocytic swelling. Clin Chem Lab Med 2000;38:1169-1172.

30. Pinto SS, Gottfried C, Mendez A, Goncalves D, Karl J, Goncalves CA, et al. Immunocontent and secretion of S100B in astrocyte cultures from different brain regions in relation to morphology. FEBS Lett 2000;466:203-207.

31. Marchi N, Cavaglia M, Fazio V, Bhudia S, Hallene K, Janigro D. Peripheral markers of blood-brain barrier damage. Clin Chim Acta 2004;342:1-12.

32. Rothermundt M, Peters M, Prehn JH, Arolt V. S100B in brain damage and neurodegeneration. Microsc Res Tech 2003;60:614-632.

33. Kogel D, Peters M, König HG, Hashemi SM, Bui NT, Arolt V, et al. S100B potently activates p65/c-Rel transcriptional complexes in hippocampal neurons: Clinical implications for the role of S100B in excitotoxic brain injury. Neuroscience 2004;127:913-920.

34. Kleindienst A, McGinn MJ, Harvey HB, Colello RJ, Hamm RJ, Bullock MR. Enhanced hippocampal neurogenesis by intraventricular S100B infusion is associated with improved cognitive recovery after traumatic brain injury. J Neurotrauma 2005;22:645-655.

35. Hetzel G, Moeller O, Evers S, Erfurth G, Ponath G, Arolt V, et al. The astroglial protein S100B and visually evoked event-related potentials before and after antidepressant treatment. Psychopharmacology (Berl) 2005;178:161-166.

36. D’Sa C, Duman RS. Antidepressant and neuroplasticity. Bipolar Disord 2002;4:183-194.

37. Tardito D, Perez J, Tiraboschi E, Musazzi L, Racagni G, Popoli M. Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanism in the action of antidepressants: a critical overview. Pharmacol Rev 2006;58:115-134.

38. Lee HY, Kim YK. Plasma Brain-Derived Neurotrophic Factor as a Peripheral Marker for the Action Mechanism of Antidepressants. Neuropsychobiology 2008;57:194-199.

39. Whitaker-Azmitia PM, Murphy R, Azmitia EC. Stimulation of astroglial 5-HT1A receptors releases the serotonergic growth factor, protein S-100, and alters astroglial morphology. Brain Res 1990;528:155-158.

40. Carson MJ, Thomas EA, Danielson PE, Satcliffe JG. The 5HT5A serotonin receptor is expressed predominantly by astrocytes in which it inhibits cAMP accumulation: a mechanism for neuronal suppression of reactive astrocytes. Glia 1996;17:317-326.

41. Porter JT, McCarthy KD. Astrocytic neurotransmitter receptors in situ and in vivo. Prog Neurobiol 1997;51:439-455.

42. Paizanis E, Hamon M, Lanfumey L. Hippocampal neurogenesis, depressive disorders, and antidepressant therapy. Neural Plast 2007;2007:73754.